Positive results in the Esperanza Covid pilot test to treat persistent covid

Persistent COVID -19 is defined as the presentation of symptoms lasting more than 4 weeks from the onset of the COVID -19 disease. Its presentation, which is not related to the severity of the acute phase, is estimated to affect 10% of patients. The most frequent symptoms are dyspnea, cough, asthenia, headache and abdominal pain among others. These patients are usually cared for in primary care.

There is currently no treatment available for persistent COVID-19.

Montelukast is a drug already marketed, indicated in the treatment of uncontrolled mild-moderate asthma, and in asthma induced by effort.

Based on the biological plausibility of the benefit of montelukast in reducing the inflammatory process produced in the SARS-CoV-2 infection, Francisco Mera Cordero, family physician at EAP El Pla, empirically treated (drug not approved with this new indication) individuals with this pathology. The pilot test was done in 12 patients for 14 days. The results obtained were positive in terms of clinical respiratory improvement, one of the most disabling symptoms, as well as other symptoms.

As a result of this experience, with the support of the Unitat de Suport a la Recerca (USR) of the DAP Costa Ponent, pharmacy referents of the SAP Baix Llobregat Center and the Unitat d'Estudi del Medicament of the IDIAP Jordi Gol, in June the elaboration of the protocol of the E-SPERANÇA-COVID-19 project.

The E-SPERANÇA-COVID19 is a Phase II, randomized and double-blind clinical trial to evaluate the efficacy of montelukast compared to placebo in improving the quality of life associated with respiratory symptoms in patients with persistent COVID-19. The trial is pending evaluation by the Spanish Agency for Medicines and Health Products (AEMPS). The study is expected to begin in the second quarter of 2021.